预测冠心病经皮冠状动脉介入治疗后冠状动脉再狭窄的长链非编码 RNA 的价值：系统评价和荟萃分析方案。
Predictive value of LncRNA on coronary restenosis after percutaneous coronary intervention in patients with coronary heart disease: A protocol for systematic review and meta-analysis.
机构信息
Department of Cardiology, Hanyang hospital of Wuhan University of Science and Technology, Hanyang, Wuhan,China.
出版信息
Medicine (Baltimore). 2021 Jan 8;100(1):e24114. doi: 10.1097/MD.0000000000024114.
BACKGROUND
Evidence shows that long-stranded non-coding RNA (LncRNA) can predict coronary artery restenosis in patients suffering from coronary heart disease after percutaneous coronary intervention, suggesting that LncRNA may become a promising biomarker for the diagnosis of coronary artery restenosis after percutaneous coronary intervention. However, its accuracy has not been systematically evaluated. Therefore, it is necessary to perform meta-analysis to certify the diagnostic value of LncRNA on coronary artery restenosis after percutaneous coronary intervention.
METHODS
PubMed, EMBASE, Cochrane Library, and Web of Science were searched for relevant studies to explore the potential diagnostic values of LncRNA on coronary artery restenosis after percutaneous coronary intervention from inception to December 2020. Data were extracted by two experienced researchers independently. The risk of bias about the meta-analysis was confirmed by the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2). Data was synthesized and heterogeneity was investigated as well. All of the above statistical analysis was carried out with Stata 14.0.
RESULTS
This study proved the pooled diagnostic performance of LncRNA on coronary artery restenosis after percutaneous coronary intervention.
CONCLUSION
This study clarified confusions about the specificity and sensitivity of LncRNA on coronary artery restenosis after percutaneous coronary intervention, thus further guiding their promotion and application.
ETHICS AND DISSEMINATION
Ethical approval is not required for this study. The systematic review will be published in a peer-reviewed journal, presented at conferences, and shared on social media platforms. This review would be disseminated in a peer-reviewed journal or conference presentations.
OSF REGISTRATION NUMBER
DOI 10.17605/OSF.IO/4QT2P.
背景
有证据表明，长链非编码 RNA（LncRNA）可预测经皮冠状动脉介入治疗后冠心病患者的冠状动脉再狭窄，表明 LncRNA 可能成为经皮冠状动脉介入治疗后冠状动脉再狭窄的有前途的诊断生物标志物。然而，其准确性尚未得到系统评估。因此，有必要进行荟萃分析以验证 LncRNA 对经皮冠状动脉介入治疗后冠状动脉再狭窄的诊断价值。
方法
从建库至 2020 年 12 月，我们检索了 PubMed、EMBASE、Cochrane 图书馆和 Web of Science 以探索 LncRNA 对经皮冠状动脉介入治疗后冠状动脉再狭窄的潜在诊断价值。由两名有经验的研究人员独立提取数据。采用诊断准确性研究质量评估-2（QUADAS-2）来确认荟萃分析的偏倚风险。对数据进行综合和异质性研究。以上所有统计分析均采用 Stata 14.0 进行。
结果
本研究证明了 LncRNA 对经皮冠状动脉介入治疗后冠状动脉再狭窄的汇总诊断性能。
结论
本研究阐明了 LncRNA 对经皮冠状动脉介入治疗后冠状动脉再狭窄的特异性和敏感性的困惑，从而进一步指导其推广和应用。
伦理与传播
本研究不需要伦理批准。系统评价将发表在同行评议的期刊上，在会议上展示，并在社交媒体平台上分享。本综述将发表在同行评议的期刊或会议报告中。
OSF 注册号：DOI 10.17605/OSF.IO/4QT2P。
Zotero 插件